Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
01:43:27 EDT Sat 20 Apr 2024
Enter Symbol
or Name
USA
CA



News for U:BLUE from 2023-04-20 to 2024-04-19 - 25 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-11 08:00U:BLUENews Releasebluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-03-26 07:01U:BLUENews Releasebluebird bio Reports Fourth Quarter and 2023 Annual Results and Highlights Operational Progress and 2024 Guidance
2024-03-25 16:05U:BLUENews Releasebluebird bio to Host Fourth Quarter and 2023 Annual Results Conference Call
2024-03-18 08:00U:BLUENews Releasebluebird bio Secures up to $175 Million Debt Financing with Hercules Capital
2024-03-11 08:00U:BLUENews Releasebluebird bio Announces First Outcomes-Based Agreement with Medicaid for Sickle Cell Disease Gene Therapy
2024-01-08 08:00U:BLUENews Releasebluebird bio Provides Update on Commercial Launch Progress, Program Milestones, and 2024 Financial Outlook
2024-01-02 08:00U:BLUENews Releasebluebird bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-19 21:41U:BLUENews Releasebluebird bio, Inc. Announces Pricing of $125 Million Public Offering of Common Stock
2023-12-18 16:01U:BLUENews Releasebluebird bio, Inc. Announces Proposed Public Offering of Common Stock
2023-12-10 12:02U:BLUENews ReleaseLong-Term Data Presented at ASH Support beti-cel as a Potentially Curative Gene Therapy for Ž ²-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels
2023-12-09 11:31U:BLUENews ReleaseLong-term Follow-up Data From bluebird ¢ € ™s Gene Therapy Program in Sickle Cell Disease Support Durable, Potentially Curative Benefits Through Stable Production of Anti-Sickling Adult Hemoglobin and Resolution of Vaso-Occlusive Events
2023-12-08 13:01U:BLUENews Releasebluebird bio Details Plans for the Commercial Launch of LYFGENIA ¢ „ ¢ Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events
2023-12-08 12:35U:BLUENews Releasebluebird bio Announces FDA Approval of LYFGENIA ¢ „ ¢ (lovotibeglogene autotemcel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events
2023-11-07 07:00U:BLUENews Releasebluebird bio Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
2023-11-02 09:37U:BLUENews Releasebluebird bio to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition
2023-10-30 08:00U:BLUENews Releasebluebird bio Enters into Advance Agreement to Sell Priority Review Voucher, if Granted, for $103 Million
2023-10-24 08:00U:BLUENews Releasebluebird bio to Host Third Quarter 2023 Financial Results Conference Call
2023-09-05 16:05U:BLUENews Releasebluebird bio Announces September Investor Events
2023-08-16 07:00U:BLUENews Releasebluebird bio Confirms That FDA Has Communicated That Advisory Committee Meeting Will Not Be Scheduled for lovo-cel Gene Therapy for Sickle Cell Disease
2023-08-08 07:00U:BLUENews Releasebluebird bio Reports Second Quarter 2023 Financial Results and Highlights Operational Progress
2023-07-25 08:00U:BLUENews Releasebluebird bio to Host Second Quarter 2023 Financial Results Conference Call and Provide Commercial Update
2023-06-21 07:00U:BLUENews Releasebluebird bio Announces FDA Priority Review of the Biologics License Application for lovotibeglogene autotemcel (lovo-cel) for Patients with Sickle Cell Disease (SCD) 12 years and Older with a History of Vaso-Occlusive Events
2023-05-09 07:00U:BLUENews Releasebluebird bio Reports First Quarter 2023 Financial Results and Highlights Operational Progress
2023-04-27 16:05U:BLUENews Releasebluebird bio Announces First Quarter 2023 Earnings Date and Upcoming Investor Events
2023-04-24 07:30U:BLUENews Releasebluebird bio Submits Biologics License Application (BLA) to FDA for lovotibeglogene autotemcel (lovo-cel) for Patients with Sickle Cell Disease (SCD) 12 years and Older with a History of Vaso-Occlusive Events